TickerGuard
Buy Day today: Good (67) Broad market participation · no major macro event

Regenxbio Inc (RGNX)

Healthcare Biotechnology
10.00 $
+2.8% vs. previous close
Closing price · As of: 3. Aug 2026

Regenxbio Inc (RGNX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q1 26), "Revenue" came in at 6.4 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Income Statement RGNX
Tick rows to compare them in a chart (up to 4) Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 LTM
20 29 22 16 22 24 21 89 21 30 30 6.4 88
9.5 12 16 8.5 15 12 6.3 3.4 9.1 62 5.9 11 88
11 17 6.6 7.2 7.7 12 15 86 12 -32 24 -4.7 -0.1
60 58 51 51 45 54 50 53 56 56 60 57 229
24 23 19 18 19 19 20 20 20 20 22 21 84
84 81 71 69 64 74 66 73 76 20 82 79 257
-73 -65 -64 -62 -56 -62 -51 12 -63 -52 -58 -83 -257
1.1 1.6 1.4 2.0 0.4 0.8 9.4 8.6 11 13 12 8.7 45
-72 -62 -63 -63 -53 -60 -51 6.1 -71 -62 -67 -90 -290
1.1 -2.7 -0.2 0.0
-72 -62 -63 -63 -53 -60 -51 6.1 -71 -62 -67 -90 -290
-67 -56 -57 -57 -48 -55 -38 19 -56 -45 -51 -77 -229

LTM = last twelve months (sum of the four most recent quarters).

Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?